Ressources
-
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
Case study
Search Results
Search across news, resources and pages to quickly find relevant content on our site.
Blog
There are many terms – not all of them complimentary – used to describe…
Journal Papers
Norbert Minet, Anne-Claire Boschat, Rebecca Lane, David Laughton, Philip Beer, Hélène Asnagli, Claire Soudais, Tim Bourne, Alain Fischer, Emmanuel Martin, Sylvain Latour Abstract…
Blog
Sygnature Discovery's oncology team reflect on recent developments in oncology drug discovery presented at this year's AACR meeting.
Blog
The human brain, an amazing organ, is responsible for controlling how we feel, what we…
Blog
Regardless of the target or modality, all drug discovery programmes commence with some form of…
Journal Papers
Maxim A X Tollenaere, Christina Mølck, Ian Henderson, Scott Pollack, Philip Addis, Helle Heibroch Petersen, Hanne Norsgaard Abstract…
Journal Papers
Sachin A Gupte, Chandra Shekhar Bakshi, Emma Blackham, Gerald E Duhamel, Allan Jordan, Padmini Salgame, Melinee D’silva, Mohammad Y Khan, Jerry Nadler, Rakhee…
Blog
Explore the Significance of Chiral Chromatography in Enantiomer Separation: An In-Depth Analysis by Alex Brien, Senior Principal Scientist of Analytical Chemistry at Sygnature Discovery.
News
Sygnature Discovery (« Sygnature »), partenaire de premier plan en matière de découverte intégrée de…
Journal Papers
Andre Bazzone, Maria Barthmes, Cecilia George, Nina Brinkwirth, Rocco Zerlotti, Valentin Prinz, Kim…
Blog
Bioavailability: What is it and what factors influence it? Bioavailability (F) is a…
News
Sygnature Discovery est ravie d’annoncer que son client, River BioMedics , a levé 2…
Blog
Dive into the world of covalent therapeutics and their promising benefits in drug development. Discover how biophysics helps us unravel their complexities and optimize their effectiveness in innovative treatments.
News
Le 10 octobre 2023, Sygnature Discovery, fournisseur mondial de premier plan de solutions…
Blog
Unlock the full potential of High-Throughput Screening (HTS) with strategic counter screens. Discover when and how to apply them effectively, ensuring precise compound selection and optimizing your drug discovery projects for success.
Blog
Explore our innovative approach to screening GPCR inverse agonists and discover the therapeutic potential of these compounds in drug discovery. Learn how we developed robust HTS assays, screened hundreds of compounds, and advanced our drug discovery pipeline with precision and efficiency.
Journal Papers
Rebecca L. Davie, Hannah J. Edwards, D. Michael Evans, Simon T. Hodgson, Michael J.
Blog
Sygnature Discovery collaborates with Insmed, bringing together their expertise to develop compounds targeting genetically defined diseases. With seamless teamwork and co-located scientific operations, they aim to create innovative therapeutics for unmet medical needs.
Journal Papers
Andrzej T Slominski, Tae-Kang Kim, Radomir M Slominski, Yuwei Song, Shariq Qayyum, Wojciech Placha, Zorica Janjetovic, Konrad Kleszczyński, Venkatram Atigadda, Yuhua Song, Chander Raman, Cornelis…
Blog
Delve into the realm of targeted protein degradation and the critical role of formulation strategies in drug development. From overcoming dissolution limitations to optimizing stability and solubility, explore the key components that ensure your molecule's clinical success. Sygnature Discovery offers comprehensive formulation support, bringing your degrader one step closer to achieving its full potential.
Support
Can't find what you're looking for?
Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.
